ClinicalTrials.gg
CompletedNCT03277456Updated Nov 14, 2017

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

An Early Phase 1 interventional study of MVA-NP+M1 in Human Volunteers, sponsored by Barinthus Biotherapeutics. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-14.

Sponsored by Barinthus Biotherapeutics · Early Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a first in human, phase I, open label study of the MVA viral vector (produced in the novel immortalised duck retinal cell line AGE1.CR.pIX) expressing the influenza antigens NP and M1 as a fusion protein, in healthy adult volunteers. MVA-NP+M1 will be given alone intramuscularly as a single dose.

There will be 1 study group and a total of 6 volunteers will be enrolled. Staggered enrollment will apply for the first three volunteers within the group.

02

Conditions studied

  • Human Volunteers
03

In context

Lead sponsor

Barinthus Biotherapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults aged 18-50
  2. Able and willing (in the Investigator's opinion) to comply with all study requirements
  3. Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
  4. For females only, willingness to practice continuous effective (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination (for women of child bearing potential only)
  5. Agreement to refrain from blood donation during the course of the study
  6. Provide written

Exclusion criteria

Exclusion Criteria:

  1. Participation in another research study involving receipt of an product in the 30 days preceding enrolment, or planned use during the study period
  2. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data.
  3. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  4. Any confirmed or suspected or immunodeficient state, including infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical are allowed)
  5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
  6. Any history of anaphylaxis in relation to vaccination
  7. Pregnancy, lactation or willingness/intention to become pregnant during the study (for women of child bearing potential only)
  8. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
  9. History of serious psychiatric condition likely to affect participation in the study
  10. Bleeding disorder (eg. Factor deficiency, coagulopathy or disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture
  11. Any other serious chronic illness requiring hospital specialist supervision
  12. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
  13. Suspected or known injecting drug abuse in the 5 years preceding enrolment
  14. Seropositive for surface antigen (HBsAg)
  15. Seropositive for virus (antibodies to HCV)
  16. Any abnormal finding on screening biochemistry and haematology blood tests or urinalysis
  17. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
  18. Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Single intramuscular injection of MVA-NP+M1 vaccine

    MVA-NP+M1, a novel vaccine will be administered intramuscular. The total volume given is 0.5ml and the dose given is 1.5E8 pfu. Each volunteer will receive one single injection only over a few seconds.

    Biological: MVA-NP+M1

Interventions

06

What researchers measure

Primary outcomes

  1. Measure of local reactogenicity following intramuscular injection of MVA-NP+M1

    Occurrence and severity of solicited local reactogenicity signs and symptoms for 7 days following vaccination using a diary card.

    Time frame: 7 days post vaccination

  2. Measure of systemic reactogenicity following intramuscular injection of MVA-NP+M1

    Occurrence and severity rating of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination using a diary card.

    Time frame: 7 days post vaccination

  3. Measure the occurrence of adverse events following intramuscular injection of MVA-NP+M1

    Occurrence and severity of unsolicited adverse events for 28 days following the vaccination using a diary card.

    Time frame: 28 days post vaccination

  4. Assessment of safety laboratory assessments following intramuscular injection of MVA-NP+M1

    Review of changes in safety laboratory measures from baseline visit to Day 2, Day 7, Day 21 and Day 28 visits

    Time frame: 28 days post vaccination

  5. Serious Adverse Events that occur during the study

    Review of causality and relationship to MVA-NP+M1 for any serious adverse events during the whole study duration

    Time frame: 28 days post vaccination

07

Study locations

1 site
  • Centre for Clinical Vaccinology and Tropical Medicine (CCVTM)
    Oxford, Oxfordshire OX3 7LJ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Nov 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2017
First posted
Sep 11, 2017
StartActual
Sep 18, 2017
Primary completionActual
Nov 2, 2017
CompletionActual
Nov 2, 2017
Last update
Nov 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03277456
Lead sponsor
Barinthus Biotherapeutics
Responsible party
Sponsor
First posted
Sep 11, 2017
Start date
Sep 18, 2017
Primary completion
Nov 2, 2017
Completion
Nov 2, 2017
Last update
Nov 14, 2017

Study contacts

Adrian Hill, MD
principal investigator · Director, The Jenner Institute, Oxford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MVA-NP+M1

Start the discussion